BCMA-mRNA疫苗是多发性骨髓瘤有前景的治疗手段
研究利用脂质纳米颗粒(LNP)包裹序列和碱基优化的BCMA mRNA,并共包裹TLR3激动剂聚肌胞苷酸[poly(I:C)],体外可被树突状细胞摄取并激活BCMA特异性CD8+细胞毒性T细胞,后者可裂解BCMA+ U266骨髓瘤细胞和CD138+患者骨髓瘤细胞;小鼠接种后诱导BCMA特异性CTL并抑制肿瘤生长,联合poly(I:C)进一步增强免疫应答。
要点
- BCMA-mRNA LNP疫苗体外激活BCMA特异性CD8+ CTL并裂解BCMA+骨髓瘤细胞。
- C57BL/6J小鼠接种后诱导脾DC活化和BCMA特异性CTL。
- 荷瘤小鼠接种抑制肿瘤生长,联合poly(I:C)进一步增强免疫应答。
核心结论
- BCMA-mRNA LNP疫苗联合poly(I:C)可诱导BCMA特异性CD8+ T细胞应答并抑制小鼠骨髓瘤生长,为临床评估提供框架。
研究设计与样本
- 研究为临床前体外与小鼠体内实验,使用BCMA mRNA-LNP疫苗及共包裹poly(I:C)的LNP制剂。
主要发现
- BCMA-mRNA LNP体外被树突状细胞内化,触发BCMA特异性CD8+ CTL增殖和活化。
- 这些CTL裂解BCMA+ U266骨髓瘤细胞和CD138+患者骨髓瘤细胞,不影响BCMA敲除U266或CD138-患者来源骨髓细胞。
- C57BL/6J小鼠接种BCMA-mRNA LNP后激活脾脏DC并诱导BCMA特异性CTL,选择性杀伤过表达BCMA的鼠5TGM1骨髓瘤细胞。
- 接种BCMA过表达5TGM1细胞的C57BL/KaLwRijHsd小鼠中,疫苗抑制肿瘤生长并伴随BCMA特异性CD8+ T细胞应答。
- 在所有情况下,联合poly(I:C)进一步触发BCMA-mRNA LNP诱导的免疫应答。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer vaccines are emerging as promising therapies to not only prevent cancer but to treat cancer. Here, we developed a therapeutic vaccine for multiple myeloma (MM) using B-cell maturation antigen (BCMA) protein as a target. Given the remarkable efficacy of COVID-19 messenger RNA (mRNA) vaccines, we first packaged sequence- and base-optimized BCMA mRNA into lipid nanoparticles (LNPs) using next-generation ionizable lipid, enhancing their accumulation in the spleen. A toll-like receptor 3 agonist, polyinosinic:polycytidylic acid [poly(I:C)], was also encapsulated in LNPs to further elicit BCMA-specific immune response. BCMA-mRNA LNPs were internalized by dendritic cells (DCs) in vitro, triggering proliferation and activation of BCMA-specific CD8+ cytolytic T cells (CTLs). Importantly, these CTLs lysed BCMA+ U266 MM cells and CD138+ patient MM cells, without affecting BCMA-knockout U266 or CD138- patient-derived bone marrow cells. Vaccination of C57BL/6J mice with BCMA-mRNA LNPs activated splenic DCs and induced BCMA-specific CTLs, assessed by tetramer staining, which selectively killed murine 5TGM1 BCMA overexpressing MM cells. Finally, vaccination of C57BL/KaLwRijHsd mice bearing BCMA-overexpressing 5TGM1 cells inhibited tumor growth associated with BCMA-specific CD8+ T-cell responses. The combination treatment with poly(I:C) further triggered the immune response induced by BCMA-mRNA LNPs in all instances. Our findings provide the framework for clinical evaluation of BCMA-mRNA LNP vaccines to improve patient outcome in MM.
引用
- Dutta D, Liu J, Wen K, et al. A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma. Blood. 2025. PMID: 40700574. doi:10.1182/blood.2025028597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。